An Act to Amend the Maine Death with Dignity Act to Ensure Access by Qualified Patients
Summary
LD 613 amends Maine’s Death with Dignity Act, which governs medical aid in dying for qualified patients. The bill changes the timing rules for making requests for life-ending medication by requiring two oral requests at least 15 days apart and a written request, while also allowing the attending physician to offer the patient a chance to rescind the request at the second oral request. It preserves the existing structure of physician oversight and documentation, but revises the waiting-period language to make clear that the written request cannot be signed earlier than 15 days after the first oral request and that at least 48 hours must pass before a prescription is written.
Impact
The bill amends 22 MRSA §2140, the Maine Death with Dignity Act statute, by repealing and replacing the subsection governing written and oral requests and waiting periods, repealing a separate subsection, and updating physician recordkeeping requirements. It also adds a new documentation requirement when a physician waives part of the waiting period, requiring a note explaining why the waiver is in the patient’s best interests and specifying the portion waived. The practical effect is to clarify and slightly adjust access to aid-in-dying medication for qualified patients while preserving a minimum total waiting period of seven days when any waiver is granted.
Sentiment
The voting history suggests the bill was controversial and closely divided, with several narrow votes on procedural motions and amendments before final enactment. The repeated reconsideration, recede-and-concur, and amendment votes indicate substantial legislative debate and shifting coalitions. Ultimately, the bill passed and was signed into law, showing enough support to enact the access-focused changes despite persistent opposition.
Contention
The main point of contention appears to have been the balance between ensuring access for qualified patients and maintaining safeguards around the timing and oversight of aid-in-dying requests. Supporters likely viewed the bill as reducing barriers and clarifying the process for patients facing terminal illness, while opponents likely objected to loosening or streamlining access to life-ending medication. The narrow vote margins on amendments and final passage indicate that both the access issue and the physician waiver authority were significant flashpoints.